ERBB2 and breast carcinoma: These studies compared the pCR rate in HER2-positive early breast cancer patients treated with either trastuzumab CT-P6 or reference trastuzumab, and found that patients treated with CT-P6 achieved pCR rates of 65% and 74.4%, respectively.